Interestingly, studies have shown that drugs (e.g., olmesartan and licochalcone A) that activate the Nrf2 signaling pathway and inhibit the NF-κB signaling pathway could significantly improve experimental colitis (Liu et al., 2018; Saber et al., 2019). The gene discussed is NFKB1; the disease is colitis.